HIM
ANIK icon

Hillsdale Investment Management’s Anika Therapeutics ANIK Stock Holding History

Hillsdale Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.03M Buy
138,821
+113,421
+447% +$1.68M 0.05% 305
2026
Q1 		$368K Buy
+25,400
New +$295K 0.01% 449
2014
Q3 		– Sell
-6,900
Closed -$320K – 541
2014
Q2 		$320K Buy
+6,900
New +$307K 0.07% 200

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Hillsdale Investment Management's ANIK Position: Q2 2026 in Review

Hillsdale Investment Management increased its Anika Therapeutics (ANIK) stake by 447% in Q2 2026, buying an estimated $1.68M and bringing the position to 138,821 shares worth $2.03M. The position accounts for 0.05% of the portfolio, ranked #305.

Hillsdale Investment Management first reported a position in ANIK in Q2 2014 and has held it in 3 quarters since. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Hillsdale Investment Management held 138,821 shares of Anika Therapeutics worth $2.03M as of Q2 2026.
  • Hillsdale Investment Management bought 113,421 Anika Therapeutics shares in Q2 2026, an estimated $1.68M.
  • Anika Therapeutics made up 0.05% of Hillsdale Investment Management's portfolio in Q2 2026, its #305 holding.
  • Hillsdale Investment Management first reported a position in Anika Therapeutics in Q2 2014 and has held it in 3 quarters since.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.